A Patient with Psoriasis and Vitiligo Treated with Etanercept

  • Anna Campanati
  • Katia Giuliodori
  • Giulia Ganzetti
  • Giulia Liberati
  • Anna Maria Offidani
Clinical Case

DOI: 10.2165/1153424-S0-000000000-00000

Cite this article as:
Campanati, A., Giuliodori, K., Ganzetti, G. et al. AM J Clin Dermatol (2010) 11(Suppl 1): 46. doi:10.2165/1153424-S0-000000000-00000

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory dermatosis whose aetiopathogenesis remains unclear, although tumour necrosis factor alpha (TNFα) appears to play a crucial role. The biological potential of TNFα inhibitors, such as etanercept, which reduce the inflammatory cascade, has radically changed the therapeutic management of patients with psoriasis and other immunomediated inflammatory diseases, associated with TNFα. The pathogenesis of the selective destruction of melanocytes in vitiligo is not fully understood, although there is growing evidence that several T helper type 1 cytokines, particularly TNFα, may be involved in the depigmentation process.

A patient is described who presented with both psoriasis and vitiligo, and was treated with etanercept. After 24 weeks of therapy, the patient’s psoriasis had improved markedly and the patient noted a mild improvement of vitiligo, with a reduction in macules and repigmentation in the scapular region.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Anna Campanati
    • 1
  • Katia Giuliodori
    • 1
  • Giulia Ganzetti
    • 1
  • Giulia Liberati
    • 1
  • Anna Maria Offidani
    • 1
  1. 1.Dermatological Clinic, Medical and Biotatistics Science DepartmentPolytechnic Marche UniversityAnconaItaly

Personalised recommendations